Latest Sanofi Press Releases and News | Sanofi
WEBAug 26, 2024 · Stay informed with the latest Sanofi press releases and news updates. Discover new developments in healthcare and pharmaceuticals with Sanofi.
Sanofi pushes ahead with €20bn consumer healthcare spin-off
WEBJun 2, 2024 · The move makes Sanofi the latest Big Pharma company to seek to separate low-margin, consumer businesses from divisions focused on innovative new medicines that offer higher returns.
Novavax shares soar on license deal with Sanofi at lofty valuation
WEBMay 10 (Reuters) - Novavax (NVAX.O) on Friday said it had struck a licensing deal worth at least $1.2 billion with Sanofi (SASY.PA) for its COVID-19 vaccine in exchange for a stake that valued...
Sanofi Enters Next Chapter of Play to Win Strategy | Sanofi
WEBOct 27, 2005 · Sanofi today provided a comprehensive update regarding its Play to Win strategy. This strategy continues to focus on the critical goals of executing transformative medicine and vaccines launches, driving agile and efficient resource deployment and enhancing R&D productivity.
Sanofi to acquire Provention Bio, adding to portfolio TZIELD, the …
WEBMar 13, 2006 · Sanofi announces agreement to acquire Provention Bio for $2.9B, adding to portfolio TZIELD® (teplizumab-mzwv). Learn more about this novel therapy.
Sanofi US News
WEB5 days ago · The risks and uncertainties also include the uncertainties discussed or identified in the public filings with the SEC and the AMF made by Sanofi, including those listed under "Risk Factors" and "Cautionary Statement Regarding Forward-Looking Statements" in Sanofi's annual report on Form 20-F for the year ended December 31, 2023. Other than as ...
Press Room - Sanofi US News
WEBMay 27, 2024 · Chief Medical Officer, Global Head of Development at Sanofi “Despite recent advancements in multiple myeloma treatment, there remains a significant unmet need for new frontline therapies, particularly for transplant-ineligible patients who can face poor outcomes from the disease.
Press Room - Sanofi US News
WEBUpdated as of October 26, 2023. There has been unprecedented demand for Beyfortus™ (nirsevimab-alip). For the first time in history, health care providers are able to help protect an extraordinary number of infants against respiratory syncytial virus (RSV) disease.
Sanofi loses $21 bln in market value after dropping 2025 profit …
WEBOct 27 (Reuters) - Sanofi (SASY.PA) stock plunged on Friday, wiping 20 billion euros ($21 billion) off its market value, after it abandoned its 2025 profit target under a plan to list its...
With amped up manufacturing effort, Sanofi and AZ look to avoid ...
WEB3 days ago · Sanofi has begun shipping the antibody in its 50 mg and 100 mg doses to private healthcare providers and the CDC's Vaccines for Children program to get ahead of the upcoming RSV season, ...